Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PORxin: Interim Phase I data

Interim data from a dose-escalation, U.S. Phase I trial in 12 patients with moderate

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE